Nano Nuclear Energy Inc.
Business
Nano Nuclear Energy Inc. is a nuclear energy and technology company developing advanced microreactors and vertically integrated nuclear fuel and transportation solutions. It offers reactor designs (KRONOS MMR™, LOKI MMR™, ZEUS™ and ODIN™), fuel processing via HALEU Energy Fuel Inc., high-capacity HALEU fuel transportation systems, and nuclear consulting and engineering services. Its key business segments include its nuclear reactor business, fuel processing business, fuel transportation business, and nuclear consultation services. It pursues demonstration, licensing and commercialization through collaborations with U.S. national labs, universities and partners and targets customers in the United States, Canada and international industrial, remote, military and institutional markets.
Summary from filing dated 2025-12-18
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2023 2023-09-30 |
|---|---|---|---|---|
| General and administrative | 30 | 7 | 5 | |
| Research and development | 15 | 4 | 2 | |
| Change in fair value of contingent consideration | 1 | −66,000 | — | |
| Loss from operations | −46 | −11 | −6 | |
| Other income | 6 | 359,002 | 32,994 | |
| Net loss | −40 | −10 | −6 | |
| Basic (per share) | −1.06 | −0.39 | −0.28 | |
| Diluted (per share) | −1.06 | −0.39 | −0.28 | |
| Basic (shares) | 38 | 26 | 22 | |
| Diluted (shares) | 38 | 26 | 22 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2023 2023-09-30 | FY 2022 2022-09-30 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 203 | 29 | — | — | |
| Accounts receivable, net | 250,000 | — | — | — | |
| Prepaid expenses | 902,861 | 833,947 | 205,857 | — | |
| Deposits, current | 250,000 | — | — | — | |
| Total current assets | 205 | 29 | 7 | — | |
| Deferred offering costs | 300,000 | — | 75,000 | — | |
| Deposits, non-current | 269,235 | 235,235 | — | — | |
| Property, plant and equipment, net | 10 | 2 | — | — | |
| Right-of-use assets | 3 | 2 | — | — | |
| Long-term investments, related party | 2 | 2 | — | — | |
| In-process research and development | 9 | — | — | — | |
| Total assets | 229 | 35 | 7 | — | |
| Accounts payable and accrued liabilities | 1 | 761,479 | 190,005 | — | |
| Due to related parties | — | 25,000 | — | — | |
| Lease liabilities, current | 534,128 | 281,352 | — | — | |
| Contingent consideration | 2 | 770,500 | — | — | |
| Total current liabilities | 4 | 2 | 225,005 | — | |
| Lease liabilities, non-current | 2 | 2 | — | — | |
| Total liabilities | 6 | 3 | 225,005 | — | |
| Preferred stock, $0.0001 par value; 25,000,000 authorized as of September 30, 2025 and September 30, 2024; none issued and outstanding as of September 30, 2025 and September 30, 2024 | — | — | — | — | |
| Common stock, $0.0001 par value; 275,000,000 authorized as of September 30, 2025 and September 30, 2024; 41,738,358 and 30,715,663 shares issued and outstanding as of September 30, 2025 and September 30, 2024, respectively | 4,173 | 3,072 | 2,319 | — | |
| Additional paid-in capital | 280 | 49 | 9 | — | |
| Accumulated deficit | −58 | −17 | −7 | — | |
| Total stockholders equity | 223 | 32 | 2 | 2 | |
| Total liabilities and stockholders equity | 229 | 35 | 7 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2023 2023-09-30 |
|---|---|---|---|---|
| Equity-based compensation | 19 | 320,257 | 2 | |
| Amortization of right-of-use assets | 295,576 | 96,532 | — | |
| Depreciation | 355,162 | 10,393 | — | |
| R&D acquisition paid-in equity | — | 786,500 | — | |
| Changes in fair value of contingent liability | 1 | — | — | |
| Prepaid expenses | −68,914 | −628,090 | −88,409 | |
| Deposits | −284,000 | −235,235 | — | |
| Accounts receivable | −250,000 | — | — | |
| Accounts payable and accrued liabilities | 553,115 | 571,474 | 87,234 | |
| Due to related parties | −25,000 | −10,000 | — | |
| Lease liabilities | −162,541 | 5,079 | — | |
| Contingent liability | — | 770,500 | — | |
| Net cash used in operating activities | −20 | −8 | −4 | |
| In-process research and development | −9 | — | — | |
| Increase in long-term investments | — | −2 | — | |
| Additions to property, plant and equipment | −8 | −2 | — | |
| Net cash used in investing activities | −18 | −4 | — | |
| Proceeds from common stock issuances | 206 | 35 | 9 | |
| Offering costs | −15 | −4 | −75,000 | |
| Proceeds from exercise of warrants | 19 | 1 | — | |
| Proceeds from exercise of stock options | 2 | 1 | — | |
| Payment of deferred offering costs | −300,000 | — | — | |
| Net cash provided by financing activities | 212 | 34 | 9 | |
| Net increase in cash | 175 | 22 | 5 | |
| Inception of Right-of-Use Asset / Lease Liability | 1 | 2 | — |